MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Government: International
Europe
*Europe: Regions
*Western Europe
Ireland
*Industry: Ireland
Biogen Inc. (NASDAQ: BIIB)*
Organization & Developments: Biogen
*Developments: Biogen
Parents
Organization & Developments: Biogen
Children
2016: As Goes Biogen So Follows The Biotech Industry - Biogen Inc. (NASDAQ:BIIB)
2016: Biogen Beats, Raises: Bye, Bye Bear Move, Hello Bull? - Biogen Inc. (NASDAQ:BIIB)
2016: Biogen Reports Q4: Analysis Of Operations And Its Pipeline
2016: Biogen Turns To UPenn Gene Therapy Pioneers in Wide-Ranging Alliance
2016: Biogen's Newer Problems; Their Relevance To The Biotech Sector - Biogen Inc. (NASDAQ:BIIB)
2016: Positive Surprise In SMA For Biogen: Taking A Starter Position In The Stock - DoctoRx
2016: Reassessing Biogen - Biogen Inc. (NASDAQ:BIIB)
2017: Biogen Earnings Top As $125,000 Drug Starts Well
2017: Biogen Positions Itself For The Future - Biogen Inc. (NASDAQ:BIIB)
2018: Biogen reports one of their drugs slowed Alzheimer's progression in a clinical trial
2018: Biogen: Spinning Around Spinraza_seekingalpha.com
2018: Biogen's Deal Is A Partial Step In The Right Direction, But A Bigger Acquisition Is In Order - Biogen Inc. (NASDAQ:BIIB)
2018: VA_65--Biogen U.S. Corporation 65IB Pharmaceutical Hematology and Related Products Effective Dates: 09/15/2018 through 09/14/2023
2019: Analyst pens a barbed note to Biogen: Shed caution, dump Alzheimer’s and retool at the top
2019: As Alzheimer’s Conference Kicks Off, All Eyes Are on Biogen’s Drug
2019: Biogen Alzheimer's Failure Is Not Surprising, More Will Follow_seekingalpha.com
2019: Biogen Reverses Course on Alzheimer’s Drug Analysis, Plans FDA Filing
2019: What Should Investors Think of Biogen's Alzheimer's Drug Candidate?
2019: Why Alzheimer's Treatment Hopes Endure Despite High-Profile Drug Failures_www.investors.com
2020: Biogen Acquires Alzhemer's and Parkinson's Asset from Pfizer in $710 Million Deal
2020: Biogen Changes The World And Grows 44%
2020: Biogen: An Undervalued Opportunity In An Overpriced Market
2020: Biogen: Neurology Leader Pivots To Gene Therapy
2020: Biogen's stock rallies 11% after FDA accepts application for experimental Alzheimer's drug
2020: Scribe Therapeutics emerges with $20M, Biogen pact to clear CRISPR hurdles
2020: UPDATED: Tally of coronavirus cases at Biogen spikes by 15 on Sunday
2021: Biogen 2021: 2 Paths Diverge
2021: Biogen shares surge 38% after FDA approves Alzheimer’s drug, the first new therapy for the disease in nearly two decades_www.cnbc.com
2021: Biogen's Long Aduhelm Game
2022: Biogen (BIIB) _Q3: 2022-10-25 Earnings Summary_seekingalpha.com
2022: Biogen (BIIB) Investor Presentation - Slideshow_seekingalpha.com
2022: Biogen: A Comprehensive Look At The Clarity AD Study Results_ seekingalpha.com
2022: Biogen: Beyond The Doom And Gloom_seekingalpha.com
2022: Biogen: Second Time's A Charm_ seekingalpha.com
2022: Biogen's Lecanemab Data Blows Alzheimer's Race Open Again_seekingalpha.com
2022: Eisai and Biogen's phase 3 Alzheimer's win puts amyloid back in the driver's seat, for now
2023: Biogen - Revised Revenue Forecasting To 2030 - New CEO Faces Major Challenges
2023: Buy Biogen For Runups To Imminent Regulatory Decisions_ seekingalpha.com
2023: With Leqembi approval in Alzheimer's disease, Eisai and Biogen plot 'meticulous' launch
2023:: Biogen's Uncertain Strategic Pivots Amidst MS Market Challenges (NASDAQ:BIIB)
2024: Beaten Down Biogen Stock Looks Attractive At Current Levels
2024: Biogen buys in to molecular glues with Neomorph deal worth up to $1.45B
2024: Biogen Holds On, But Growth Slips Through Its Fingers_ seekingalpha.com
2024: Biogen Inc. 2023 Q4 - Results - Earnings Call Presentation
2024: Biogen optimistic as new products gain traction
2024: Biogen Q3 Earnings Review: Why I Remain Optimistic Despite Difficult Quarter_ seekingalpha.com
2024: Biogen, UCB report phase 3 lupus win, justifying risky bet on asset that failed earlier trial
2024: Biogen: Q2 Earnings, Share Price May Have Bottomed Out As CEO Makes Mark_ seekingalpha
2024: Biogen's Q4 Earnings Disappoint Amidst Strategic Challenges (Rating Downgrade)
2024: Donanemab approval would fuel growth of amyloid-blocking Alzheimer’s drugs, analysts say
2025: FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Jumps
*Organization: Biogen
Developments: Biogen (Archives 2011 -2015)